• 1
    Ishikawa A, Flechner SM, Goldfarb DA, et al. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 1999; 68: 1318.
  • 2
    Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857.
  • 3
    Pelletier RP, Cosio F, Henry ML, et al. Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival time. Clin Transplant 1998; 12: 543.
  • 4
    Ferguson R. Acute rejection episodes–best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328.
  • 5
    Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
  • 6
    Tullius SG, Nieminen M, Bechstein WO, et al. Contribution of early acute rejection episodes to chronic rejection in a rat kidney retransplantation model. Kidney Int 1998; 53: 465.
  • 7
    Benfield MR, Herrin J, Feld L, Rose S, Stablein D, Tejani A. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67: 544.
  • 8
    Mengel M, Mueller I, Behrend M, et al. Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. Transpl Int 2004; 17: 293.
  • 9
    Sharma AK, Rustom R, Evans A, et al. Utility of serial Doppler ultrasound scans for the diagnosis of acute rejection in renal allografts. Transpl Int 2004; 17: 138.
  • 10
    Wever PC, Boonstra JG, Laterveer JC, et al. Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 1998; 66: 259.
  • 11
    Wever PC, Spaeny LH, Van Der Vliet HJ, et al. Expression of granzyme B during primary cytomegalovirus infection after renal transplantation. J Infect Dis 1999; 179: 693.
  • 12
    Suresh V, Carey BS, Shaw S, et al. A retrospective study of the prognostic impact of cytokine secretion in mixed lymphocyte culture on long-term graft function following allogeneic renal transplantation. Transpl Int 2005; 18: 1067.
  • 13
    Srinivas TR, Kubilis PS, Croker BP. Macrophage index predicts short-term renal allograft function and graft survival. Transpl Int 2004; 17: 195.
  • 14
    Poindexter NJ, Steward NS, Shenoy S, et al. Cytolytic T lymphocytes from human renal allograft biopsies are tissue specific. Hum Immunol 1995; 44: 43.
  • 15
    Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66: 562.
  • 16
    Rukavina D, Balen-Marunic S, Rubesa G, Orlic P, Vujaklija K, Podack ER. Perforin expression in peripheral blood lymphocytes in rejecting and tolerant kidney transplant recipients. Transplantation 1996; 61: 285.
  • 17
    Simon T, Opelz G, Wiesel M, Ott RC, Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 2003; 3: 1121.
  • 18
    Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695.
  • 19
    Robertson H, Wheeler J, Kirby JA, Morley AR. Renal allograft rejection –in situ demonstration of cytotoxic intratubular cells. Transplantation 1996; 61: 1546.
  • 20
    Porter CJ, Ronan JE, Cassidy MJ. fas-fas-ligand antigen expression and its relationship to increased apoptosis in acute renal transplant rejection. Transplantation 2000; 69: 1091.
  • 21
    Pascoe MD, Marshall SE, Welsh KI, Fulton LM, Hughes DA. Increased accuracy of renal allograft rejection diagnosis using combined perforin, granzyme B, and Fas ligand fine-needle aspiration immunocytology. Transplantation 2000; 69: 2547.
  • 22
    Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947.
  • 23
    Dadhania D, Muthukumar T, Ding R, et al. Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. Transplantation 2003; 75: 1752.
  • 24
    Ding R, Li B, Muthukumar T, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 2003; 75: 1307.
  • 25
    Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15: 219.
  • 26
    Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
  • 27
    Soulillou JP. Immune monitoring for rejection of kidney transplants. N Engl J Med 2001; 344: 1006.
  • 28
    Racusen LC. The banff schema and differential diagnosis of allograft dysfunction. Transplant Proc 2004; 36: 753.
  • 29
    Ferrand C, Robinet E, Contassot E, et al. Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther 2000; 11: 1151.
  • 30
    Bonner TI, Kerby SB, Sutrave P, Gunnell MA, Mark G, Rapp UR. Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 1985; 5: 1400.
  • 31
    Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 2004; 77: 1866.
  • 32
    Steen AM, Luthman H, Hellgren D, Lambert B. Levels of hypoxanthine phosphoribosyltransferase RNA in human cells. Exp Cell Res 1990; 186: 236.
  • 33
    Hashimoto S, Kobayashi A, Kooguchi K, Kitamura Y, Onodera H, Nakajima H. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 237.
  • 34
    Van Den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol 2000; 85: 681.
  • 35
    Lauw FN, Simpson AJ, Hack CE, et al. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria. J Infect Dis 2000; 182: 206.
  • 36
    Jerome KR, Chen Z, Lang R, et al. HSV and glycoprotein J inhibit caspase activation and apoptosis induced by granzyme B or Fas. J Immunol 2001; 167: 3928.
  • 37
    Balkow S, Kersten A, Tran TT, et al. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 2001; 75: 8781.
  • 38
    Sandberg JK, Fast NM, Nixon DF. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol 2001; 167: 181.
  • 39
    Ten Berge IJ, Wever PC, Wolbink AM, et al. Increased systemic levels of soluble granzymes A and B during primary cytomegalovirus infection after renal transplantation. Transplant Proc 1998; 30: 3972.
  • 40
    Ten Berge IJ, Wever PC, Rentenaar RJ, et al. Selective expansion of a peripheral blood CD8+ memory T cell subset expressing both granzyme B and l-selectin during primary viral infection in renal allograft recipients. Transplant Proc 1998; 30: 3975.
  • 41
    Simon T, Opelz G, Weimer R, et al. The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant 2003; 17: 217.
  • 42
    Medeiros M, Sharma VK, Ding R, et al. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods 2003; 279: 135.